Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

Technology appraisal guidance
Reference number: TA161
Published: 27 October 2008
Last updated: 07 February 2018

TA161 Osteoporosis - secondary prevention including strontium ranelate: Appendix B - GE decision paper - March 2014

TA161 Osteoporosis - secondary prevention including strontium ranelate: Appendix B - GE decision paper - March 2014

TA161 Osteoporosis - secondary prevention including strontium ranelate: Appendix B - GE decision paper - March 2014
24 March 2014
(309.46 Kb 30 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 21 March 2014